Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to provide significant cardiovascular protection in patients with type 2 DM (T2DM). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.